Nanobiotix S.A. (EPA:NANO)
33.50
+4.85 (16.93%)
At close: Mar 9, 2026
Nanobiotix Revenue
Nanobiotix had revenue of 26.64M EUR in the half year ending June 30, 2025, with 708.93% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M, down -119.86%.
Revenue (ttm)
10.16M
Revenue Growth
-75.93%
P/S Ratio
136.58
Revenue / Employee
98.63K
Employees
103
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
| Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DBV Technologies | 4.69M |
| Inventiva | 16.97M |
| Valneva SE | 179.91M |
| MedinCell | 32.44M |
| Genfit | 45.13M |
| ABIVAX Société Anonyme | 5.31M |
| Cellectis | 70.36M |
| Transgene | 7.58M |
Nanobiotix News
- 12 days ago - NANOBIOTIX to Participate in Investor Conferences in March - GlobeNewsWire
- 20 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 4 weeks ago - Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News - GuruFocus
- 7 weeks ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 2 months ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris - GlobeNewsWire
- 3 months ago - Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook - GlobeNewsWire
- 3 months ago - Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue - The Motley Fool